158 related articles for article (PubMed ID: 37478531)
1. Real-world study of disease-free survival & patient characteristics associated with disease-free survival in early-stage non-small cell lung cancer: A retrospective observational study.
Shah A; Apple J; Belli AJ; Barcellos A; Hansen E; Fernandes LL; Zettler CM; Wang CK
Cancer Treat Res Commun; 2023; 36():100742. PubMed ID: 37478531
[TBL] [Abstract][Full Text] [Related]
2. EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.
Sara Kuruvilla M; Liu G; Syed I; Gwadry-Sridhar F; Sheffield BS; Sachdeva R; Pencz A; Zhan L; Hueniken K; Patel D; Balaratnam K; Khan K; Grant B; Noy S; Singh K; Liu L; Rakibuz-Zaman M; Moldaver D; Kate Shanahan M; Cheema PK
Lung Cancer; 2022 Nov; 173():58-66. PubMed ID: 36152478
[TBL] [Abstract][Full Text] [Related]
3. SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Pennell NA; Neal JW; Chaft JE; Azzoli CG; Jänne PA; Govindan R; Evans TL; Costa DB; Wakelee HA; Heist RS; Shapiro MA; Muzikansky A; Murthy S; Lanuti M; Rusch VW; Kris MG; Sequist LV
J Clin Oncol; 2019 Jan; 37(2):97-104. PubMed ID: 30444685
[TBL] [Abstract][Full Text] [Related]
4. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study.
Chouaid C; Danson S; Andreas S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Price M; Chirila C; Hollis K; Sweeney C; Wolowacz S; Kaye JA; Kontoudis I
Lung Cancer; 2018 Oct; 124():310-316. PubMed ID: 30119925
[TBL] [Abstract][Full Text] [Related]
6. Treatment Patterns and Health Resource Utilization Among Patients Diagnosed With Early Stage Resected Non-Small Cell Lung Cancer at US Community Oncology Practices.
Buck PO; Saverno KR; Miller PJ; Arondekar B; Walker MS
Clin Lung Cancer; 2015 Nov; 16(6):486-95. PubMed ID: 25681298
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non-small cell lung cancer treated with adjuvant therapies in a community oncology setting: A real-world retrospective observational study.
Cai B; Fulcher N; Boyd M; Spira A
Thorac Cancer; 2021 Jul; 12(14):2055-2064. PubMed ID: 34028984
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non-small cell lung cancer.
West H; Hu X; Zhang S; Song Y; Chirovsky D; Gao C; Lerner A; Jiang A; Signorovitch J; Samkari A
J Manag Care Spec Pharm; 2023 Jul; 29(7):749-757. PubMed ID: 37404067
[No Abstract] [Full Text] [Related]
9. Treatment Patterns and Outcomes in Resected Early-stage Non-small Cell Lung Cancer: An Analysis of the SEER-Medicare Data.
West H; Hu X; Zhang S; Song Y; Chirovsky D; Gao C; Lerner A; Jiang A; Signorovitch J; Samkari A
Clin Lung Cancer; 2023 May; 24(3):260-268. PubMed ID: 36641325
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
Xie H; Wang H; Xu L; Li M; Peng Y; Cai X; Feng Z; Ren W; Peng Z
Clin Lung Cancer; 2018 Nov; 19(6):484-492. PubMed ID: 30369426
[TBL] [Abstract][Full Text] [Related]
11. Real-world adjuvant chemotherapy patterns and outcomes among elderly patients with resected early non-small-cell lung cancer in the USA.
Lee JM; Wang R; Johnson A; Ogale S; Kent M; Lee JS
Future Oncol; 2023 Jan; 19(1):37-47. PubMed ID: 36662515
[TBL] [Abstract][Full Text] [Related]
12. The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report.
Hardenberg MC; Patel B; Matthews C; Califano R; Garcia Campelo R; Grohe C; Hong MH; Liu G; Lu S; de Marinis F; Pérol M; Soo RA; Stiles BM; Tiseo M; Tsuboi M
ESMO Open; 2022 Oct; 7(5):100572. PubMed ID: 36108559
[TBL] [Abstract][Full Text] [Related]
13. Impact of age on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer.
Zhai X; Yang L; Chen S; Zheng Q; Wang Z
Cancer Med; 2016 Sep; 5(9):2286-93. PubMed ID: 27367482
[TBL] [Abstract][Full Text] [Related]
14. Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non-small cell lung cancer.
Zhang P; Duan J; Bai H; Wang Z; Gao S; Tan F; Gao Y; Wang X; Wan R; Xu J; He X; Feng X; Yu R; Sun J; Zhao Z; Fei K; Li N; He J; Wang J
Thorac Cancer; 2021 Jan; 12(1):30-39. PubMed ID: 33111432
[TBL] [Abstract][Full Text] [Related]
15. Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer.
Brandt WS; Yan W; Leeman JE; Tan KS; Park BJ; Adusumilli PS; Bott MJ; Molena D; Isbell J; Chaft J; Rimner A; Jones DR
Ann Thorac Surg; 2018 Sep; 106(3):848-855. PubMed ID: 29807005
[TBL] [Abstract][Full Text] [Related]
16. Clinical and economic impact of recurrence in early-stage non-small-cell lung cancer following complete resection.
West H; Hu X; Chirovsky D; Walker MS; Wang Y; Kaushiva A; Tepsick J; Samkari A
Future Oncol; 2023 Jun; 19(20):1415-1427. PubMed ID: 37218514
[TBL] [Abstract][Full Text] [Related]
17. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Yue D; Xu S; Wang Q; Li X; Shen Y; Zhao H; Chen C; Mao W; Liu W; Liu J; Zhang L; Ma H; Li Q; Yang Y; Liu Y; Chen H; Wang C
Lancet Respir Med; 2018 Nov; 6(11):863-873. PubMed ID: 30150014
[TBL] [Abstract][Full Text] [Related]
19. Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis.
Brandt WS; Yan W; Zhou J; Tan KS; Montecalvo J; Park BJ; Adusumilli PS; Huang J; Bott MJ; Rusch VW; Molena D; Travis WD; Kris MG; Chaft JE; Jones DR
J Thorac Cardiovasc Surg; 2019 Feb; 157(2):743-753.e3. PubMed ID: 30415902
[TBL] [Abstract][Full Text] [Related]
20. Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations.
Yao S; Zhi X; Wang R; Qian K; Hu M; Zhang Y
Thorac Cancer; 2016 Sep; 7(5):543-548. PubMed ID: 27766784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
